-+ 0.00%
-+ 0.00%
-+ 0.00%

Coya Therapeutics to present Phase 2 ALSTARS trial design for COYA 302 in ALS at June summit

PUBT·05/27/2026 12:05:17
Listen to the news
Coya Therapeutics to present Phase 2 ALSTARS trial design for COYA 302 in ALS at June summit
  • Coya Therapeutics will present the design of its ongoing Phase 2 ALSTARS trial of COYA 302 in amyotrophic lateral sclerosis at the 5th ALS Drug Development Summit in Boston on June 3, 2026.
  • The presentation will outline the study’s precision immunomodulatory approach aimed at regulatory T cells to address neuroinflammation in ALS.
  • No trial results were disclosed in the announcement.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260527446509) on May 27, 2026, and is solely responsible for the information contained therein.